Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01203891 · ClinicalTrials.gov registry record
Single Photon Emission Computed Tomography of the Normal Human Brain
A clinical trial of Normal Human Subjects, sponsored by Amen Clinics.
- Completed
- Registry status
- 97
- Enrollment target
- 1
- Study location
NCT01203891: Completed study of Normal Human Subjects, sponsored by Amen Clinics.
NCT01203891 is a study of Normal Human Subjects that has completed, run by Amen Clinics. The registered enrollment target is 97 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01203891, a study of Normal Human Subjects, has completed, sponsored by Amen Clinics.
- COMPLETED
- Registry status
- 97 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of the study is to acquire a database of Single Photon Emission Computed Tomographic (SPECT) studies of the brains of normal human subjects in resting and concentrating states. The database will provide a basis for subsequent investigation of meaningful brain differences between clinical and normal subject groups
Primary Outcome
For the baseline resting study with adult subjects approximately 20 milliCuries of Tc-99m-hexamethylpropylene amine oxime (HMPAO, commercially marketed by Amersham Pharmaceuticals under the trade name Ceretec) will be injected after the initial equilibration period. Ceretec is an FDA-approved functional brain imaging radiopharmaceutical currently widely commercially available.
Conditions Studied
Study Locations (1)
California
- Amen Clinics, Inc. - Newport Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2003-01 |
| Est. Completion | 2010-05 |
What the finished NCT01203891 record still lists
NCT01203891 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 97 participants, a relatively small participant target.
The record links to 1 condition, with Normal Human Subjects appearing as the primary indexed condition, and to 0 interventions.
NCT01203891 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01203891 about?
NCT01203891 is a clinical study titled "Single Photon Emission Computed Tomography of the Normal Human Brain". The objective of the study is to acquire a database of Single Photon Emission Computed Tomographic (SPECT) studies of the brains of normal human subjects in resting and concentrating states. The database will provide a basis for subsequent investigation of meaningful brain differences between clinic...
What is the current status of trial NCT01203891?
This trial is currently completed. The enrollment target is 97 participants. The study started on 2003-01. Estimated completion is 2010-05.
What conditions does trial NCT01203891 study?
This clinical trial studies the following conditions: Normal Human Subjects.
Who is sponsoring clinical trial NCT01203891?
This trial is sponsored by Amen Clinics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01203891 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03948490 · 97 participants · NA
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
- NCT04140487 · 97 participants · Phase 1
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT04196413 · 97 participants · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
- NCT05223816 · 97 participants · Phase 2
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia